Elite in Optic Nerve Atrophy

Catherine Clermont-Vignal

Paris, FR 
Elite in Optic Nerve Atrophy
Paris, FR 
OverviewLocationsClinical Research

Overview

Catherine Clermont-Vignal practices in Paris, France. Ms. Clermont-Vignal is rated as an Elite expert by MediFind in the treatment of Optic Nerve Atrophy. Her top areas of expertise are Leber Hereditary Optic Neuropathy (LHON), Optic Nerve Atrophy, Papilledema, Juvenile Temporal Arteritis, and Nerve Decompression.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles and participated in 3 clinical trials in the study of Optic Nerve Atrophy.

Gender
Female

Locations

Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Genetic, Other
Study Phase: Phase 3
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Biological, Device
Study Phase: Phase 3
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Enrollment Status: Completed
Publish Date: January 23, 2020
Intervention Type: Biological, Device
Study Phase: Phase 3
View 2 Less Clinical Trials

64 Total Publications

Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.
Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.
Journal: Investigative ophthalmology & visual science
Published: July 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Clermont-Vignal's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile